Zusduri Approved for Recurrent Low-Grade Intermediate-Risk Non–Muscle-Invasive Bladder Cancer

The FDA has approved Zusduri for adult patients with recurrent low-grade intermediate-risk ...

JUNE 15, 2025

FDA Approves Imfinzi for Muscle-Invasive Bladder Cancer

The FDA has approved Imfinzi with gemcitabine and cisplatin as neoadjuvant treatment for adults with ...

APRIL 2, 2025

Anktiva Approved for BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer

The FDA approved nogapendekin Anktiva with Bacillus Calmette-Guérin for adult patients with BCG-unresponsive ...

APRIL 24, 2024

Ferring Announces Full Availability of Adstiladrin in the U.S.

Ferring Pharmaceuticals announced that Adstiladrin is now fully available across the U.S. for adult patients with ...

JANUARY 18, 2024

FDA Approves Adstiladrin, First Gene Therapy for Bladder Cancer

Adstiladrin is the first gene therapy for adults with high-risk bacillus Calmette-Guérin (BCG)-unresponsive ...

DECEMBER 20, 2022

Padcev Granted Regular Approval for Locally Advanced or Metastatic UC

The FDA approved enfortumab vedotin-ejfv (Padcev, Astellas Pharma) to treat some adults with locally advanced or ...

JULY 19, 2021

FDA Approves Imfinzi for Advanced Bladder Cancer

Durvalumab is a human monoclonal antibody directed against programmed death ligand-1 (PD-L1), which blocks the ...

MAY 3, 2017